Loading
Cellular Immunotherapy · Journal article
Journal of Translational Autoimmunity · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of CAR-T cell therapy for refractory systemic lupus erythematosus that proposes a mechanistic framework linking B-cell depletion to broader immune reprogramming. The authors suggest CAR-T therapy may achieve durable treatment-free remission beyond conventional immunosuppression, but the source presents no primary efficacy or safety data and remains conceptual and exploratory.
Narrative review. Systemic lupus erythematosus, including refractory disease; discussion of immune pathogenesis and current treatment landscape.. Intervention: Chimeric antigen receptor T-cell (CAR-T) therapy, including conventional and next-generation approaches..
Current standard immunosuppressive and biologic therapies achieve clinical remission on treatment in only 15.6%–49.6% of SLE patients; rates of off-treatment remission are considerably lower. Rituximab fails to eliminate tissue-resident B cells and long-lived plasma cells, resulting in interpatient variability in B-cell depletion depth and frequent disease relapse after treatment cessation. Belimumab achieved a 52-week SRI-4 response rate of 57.6% in the BLISS-52 trial.
Source is a review article and does not report primary clinical trial results, efficacy endpoints, or safety data for CAR-T in SLE. Durability and long-term safety of CAR-T in SLE remain unspecified in the material provided.
This review presents CAR-T therapy as a conceptual advance but does not yet provide evidence that clinicians should adopt it in routine SLE care. The cited data on conventional and biologic therapies illustrate why novel approaches are needed; primary CAR-T efficacy and safety data from the source text are absent.
This is a narrative review synthesizing mechanistic concepts and early clinical data on CAR-T therapy for SLE, raising therapeutic possibilities rather than reporting a definitive trial or meta-analysis with hard clinical endpoints.
As stated by the source record.
Quoted from the source exactly as published.
This review presents CAR-T therapy as a conceptual advance but does not yet provide evidence that clinicians should adopt it in routine SLE care. The cited data on conventional and biologic therapies illustrate why novel approaches are needed; primary CAR-T efficacy and safety data from the source text are absent.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which current immunosuppressive and biologic therapies often fail to achieve durable remission in refractory patients. The emergence of chimeric antigen receptor T-cell (CAR-T) therapy has introduced a fundamentally new therapeutic concept, shifting therapeutic strategies from transient immune suppression toward the possibility of durable immune reprogramming. Recent studies suggest that the benefit of CAR-T therapy extends beyond depletion of autoreactive B cells. By depleting disease-associated immune cell populations and promoting immune reconstitution, CAR-T therapy may contribute to immune reprogramming, providing a potential biological basis for sustained treatment-free remission. In this review, we summarize the rapidly evolving landscape of CAR-based therapies for SLE, including conventional and next-generation strategies, and discuss their mechanisms, clinical efficacy, durability, and safety. We further highlight emerging approaches aimed at improving precision, accessibility, and long-term outcomes. Rather than serving solely as a B-cell-depleting therapy, CAR-T may represent a platform for immune reprogramming. Future advances in target selection, biomarker-guided patient stratification, and engineered cellular platforms may further improve the precision and durability of CAR-based therapies, with the long-term goal of achieving durable immune reprogramming and treatment-free remission.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.